- Home
- PETZ vs CING Comparison
PETZ vs CING Comparison
Compare PETZ & CING Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- PETZ
- CING
- Stock Information
- Founded
- PETZ 2002
- CING 2012
- Country
- PETZ China
- CING United States
- Employees
- PETZ N/A
- CING N/A
- Industry
- PETZ Steel/Iron Ore
- CING Biotechnology: Pharmaceutical Preparations
- Sector
- PETZ Industrials
- CING Health Care
- Exchange
- PETZ Nasdaq
- CING Nasdaq
- Market Cap
- PETZ 12.9M
- CING 13.1M
- IPO Year
- PETZ 2017
- CING 2021
- Fundamental
- Price
- PETZ $1.10
- CING $3.82
- Analyst Decision
- PETZ
- CING Strong Buy
- Analyst Count
- PETZ 0
- CING 3
- Target Price
- PETZ N/A
- CING $16.00
- AVG Volume (30 Days)
- PETZ 8.7K
- CING 75.2K
- Earning Date
- PETZ 04-28-2025
- CING 05-07-2025
- Dividend Yield
- PETZ N/A
- CING N/A
- EPS Growth
- PETZ N/A
- CING N/A
- EPS
- PETZ N/A
- CING N/A
- Revenue
- PETZ $3,278,453.00
- CING N/A
- Revenue This Year
- PETZ N/A
- CING N/A
- Revenue Next Year
- PETZ N/A
- CING N/A
- P/E Ratio
- PETZ N/A
- CING N/A
- Revenue Growth
- PETZ 2.46
- CING N/A
- 52 Week Low
- PETZ $1.03
- CING $1.80
- 52 Week High
- PETZ $1.74
- CING $20.83
- Technical
- Relative Strength Index (RSI)
- PETZ 40.27
- CING 46.26
- Support Level
- PETZ $1.10
- CING $3.91
- Resistance Level
- PETZ $1.20
- CING $4.44
- Average True Range (ATR)
- PETZ 0.07
- CING 0.29
- MACD
- PETZ -0.02
- CING 0.03
- Stochastic Oscillator
- PETZ 18.97
- CING 43.65
About PETZ TDH Holdings Inc.
TDH Holdings Inc is engaged in the business of manufacturing and selling of petfood and restaurant operations. The company has two operating segments which include Petfood sales and Restaurant business. It has a focus on the Restaurant business segment and generates the majority of its revenue.
About CING Cingulate Inc.
Cingulate Inc is a clinical-stage biopharmaceutical company utilizing its proprietary precision timed-release drug delivery platform to build and advance a pipeline of next-generation pharmaceutical products designed to improve the lives of patients suffering from frequently diagnosed conditions characterized by burdensome daily dosing regimens and suboptimal treatment outcomes. The company focuses on the treatment of Attention Deficit/Hyperactivity Disorder (ADHD) and anxiety, and identifying and evaluating additional therapeutic areas to use PTR technology to develop future product candidates.